Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1 [5]

AIDS

Volumn 17, Issue 9, 2003, Pages 1413-1414

  Moreno, Santiago ^a   Casado, José L ^a   Pérez Elías, María J ^a   Dronda, Fernando ^a   Antela, Antonio ^a   Moreno, Ana ^a   Gutiérrez, Carolina ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

DRUG SENSITIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DELAVIRDINE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037661154     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200306130-00026     Document Type: Letter

References (7)

1. Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 2002, 16:F41-F47.
2. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 2002, 16:F33-F40.
3. Moreno S, Casado JL, Antela A, Pérez Elías MJ, García Arata I, Dronda F, et al. Decreased susceptbility, not hypersensitivity, to non-nucleoside reverse transcriptase inhibitors in patients treated with nucleoside analogues. In: Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [Abstract 454].
4. Casado JL, Dronda F, Hertogs K, Sabido R, Antela A, Martí-Belda P, et al. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir and indinavir failure. AIDS Res Hum Retroviruses 2001, 17:93-98.
5. Clevenbergh P, Cua E, Dam E, Durant J, Schmit JC, Boulme R, et al. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naive HIV-infected patients. HIV Clin Trials 2002, 3: 36-44.
6. Harrigan R, Verbiest W, Larder B. Impact of moderate decreases in baseline NNRTI susceptibility on response to antirretroviral therapy. Antiviral Ther 2000, 5 (Suppl. 3):68-69.
7. Bacheler L, Ploughman L, Hertogs K, Larder B. Impact of baseline NNRTI resistance on the efficacy of efavirenz-combination therapy in NNRTI therapy-naive patients. Antiviral Ther 2000, 5 (Suppl. 3):70.